Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market
November 10, 2014
- Bayer, Kyoto Univ. to Hold First Collaborative Meeting by March
November 7, 2014
- Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales
November 7, 2014
- Ono to Copromote Opdivo with Bristol-Myers in Japan: President
November 7, 2014
- Trebananib Fails to Demonstrate Improvement in OS in PIII Study for Recurrent Ovarian Cancer: Takeda
November 7, 2014
- Toray Medical Files Nalfurafine for Pruritus Associated with Chronic Hepatic Disease
November 7, 2014
- Daiichi Sankyo to Cut Japan Jobs to Brace for Olmetec Patent Expiry
November 6, 2014
- Lorcaserin Confirms POC as Potential Smoking Cessation Aid in PII Study in US: Eisai
November 6, 2014
- Alfresa Transfers Part of Shares of Vaccine-Related Subsidiary to 5 Drug Makers
November 6, 2014
- LEO Pharma to Develop JT’s JAK inhibitor for Skin Disorders Outside Japan
November 6, 2014
- Overseas Growth Boosts Combined Sales of Four Major Drug Makers
November 6, 2014
- Sawai Wins Livalo Trademark Suit
November 6, 2014
- Astellas, Dana-Farber Cut Deal on KRAS Inhibitor Development
November 6, 2014
- Astellas Ties Up with US Biotech on Therapies Modulating Unfolded Protein Response
November 6, 2014
- Terumo Seeks Japan Approval of Cell Sheets for Severe Heart Failure
November 6, 2014
- Takeda, Intra-Cellular Therapies End Collaboration on PDE1 Inhibitors
November 6, 2014
- US FDA Advisory Committee Backs Approval of Edoxaban: Daiichi Sankyo
November 6, 2014
- Kyowa Kirin Completes Construction of New Product Manufacturing Facility at Takasaki Plant
November 5, 2014
- Daiichi Sankyo Posts 30.6% Rise in First-Half Operating Profit, 1.7% in Revenue
November 4, 2014
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…